Medical ConditionsBleeding & blood: Li-Fraumeni syndrome
Medical ConditionsBleeding & blood: Li-Fraumeni syndrome
Li-Fraumeni syndrome
Overview
Board takeaway: Investigate atypical persistent lesions and use clinically justified imaging; coordinate care with the cancer-surveillance and treatment teams.
What causes Li-Fraumeni syndrome?
A germline TP53 pathogenic variant causes an autosomal dominant cancer-predisposition syndrome, sometimes de novo. The tumor-suppressor defect increases risk for early-onset cancers and multiple primary tumors. Family history can be suggestive but is not required in every affected patient.
Which cancers are associated with Li-Fraumeni syndrome?
Soft tissue sarcoma, osteosarcoma, brain tumors, adrenocortical carcinoma, early breast cancer, and leukemia are important associations. Risk varies with variant, age, sex, and family context. Medical genetics determines diagnosis and the surveillance plan.
What oral findings should prompt evaluation in Li-Fraumeni syndrome?
An unexplained mass, persistent swelling or ulcer, atypical pain, progressive bone change, or delayed healing needs assessment. The syndrome does not create a specific routine dental phenotype. Prior cancer treatment can produce mucositis, dry mouth, developmental defects, or altered jaw growth and healing.
How should radiographs and dental procedures be planned in Li-Fraumeni syndrome?
Use ionizing imaging only when clinically justified and select the lowest exposure that answers the question. Review prior images and consider suitable alternatives, while retaining needed diagnostic information. Do not impose a blanket ban on dental radiographs. Invasive treatment planning follows current cancer therapy, blood counts, medication, and any prior jaw radiation or surgery.
What treatment and prognosis apply to Li-Fraumeni syndrome?
Specialist surveillance seeks early detection, often using nonionizing modalities. Cancer treatment balances disease control against secondary-malignancy risk; avoiding radiation is a preference when clinically feasible, not an absolute rule that overrides effective cancer treatment. Prognosis depends on cancers, stage, and response. The dental team supports early recognition and continued preventive care.